The Future of Therapy?
Edited by James Mittra, Christopher-Paul Milne
Pan Stanford Publishing – 2013 – 294 pages
This book brings together a range of academic, industry and practitioner perspectives on translational medicine (TM). It enhances conceptual and practical understanding of the emergence and progress of the field and its potential impact on basic research, therapeutic development, and institutional infrastructure. In recognition of the various implications TM has for public health policy and commercial innovation, the book addresses the major systemic aspects of the field. The contributors explore the dynamic interactions and key challenges in translating new science into viable therapies for the clinic, which includes recognizing the importance of social, commercial, and regulatory environments in addition to good science.
"This is a book that should be read by all those aiming to improve the efficiency and effectiveness of translation of science into clinical practice and health outcomes. Unlike other contributions in the field, it takes a holistic approach to the problem and recognises the dynamic nature of demand for as well as supply of health innovation, identifying strategies to integrate the two. This book has been needed for some time, but, with stagnating productivity and ever-increasing economic pressures, never more so than right now."
—Prof. Iain Gillespie, The University of Edinburgh, UK
Introduction to Translational Medicine
James Mittra and Christopher-Paul Milne
Drivers and Barriers to Translational Medicine
New Light Through an Old Window? The "Translational Turn" in Biomedical Research — A Historical Perspective
Translational Medicine: The Industry Perspective
Christopher-Paul Milne, Christine Kohn
Drivers and Barriers of Translational Medicine: A Regulatory Perspective
Partha Roy, Atul Bhattaram, and Shiew Mei Huang
Developing an Evaluation Model for Translational Medicine Research Programs
State of the Art in Science and Technology
Emerging Concepts in Biomarker Discovery: Cancer Immunotherapy and Degenerative Diseases of the Eye as Model Systems
Robert B. Nussenblatt, and Francesco M. Marincola
Imaging Biomarkers for Innovative Drug Development: Translation from Bench to Bedside and Back
Translational Bioinformatics: Bridging the Biological and Clinical Divide
Indra Neil Sarkar
Institutional Dynamics of Translational Medicine
Exploiting Translational Medicine Through Public–Private Partnerships: A Case Study of Scotland’s Translational Medicine Research Collaboration (TMRC)
The Role of the Product Development Partnership as a Translational Mechanism for Delivering Health Solutions in Low-Resource Settings
Julius Mugwagwa, Rebecca Hanlin, Joanna Chataway, and Lois Muraguri
Is Translational Medicine the Future of Therapy?
Christopher-Paul Milne and James Mittra
James Mittra is a research fellow and lecturer at the ESRC Innogen Centre and Science, Technology and Innovation Studies subject group at the University of Edinburgh. His research and teaching focuses on interdisciplinary approaches to the complex and dynamic ways in which life sciences are affecting the nature and the process of technological and therapeutic innovation within the pharmaceutical and biotechnology sectors. Dr. Mittra has published widely on issues of the strategic management and governance of the life sciences, as well as on mapping new value systems and business models for novel therapies.
Christopher-Paul Milne is director of research at the Tufts Center for the Study of Drug Development. His current research interests include academic–industry collaborations; disease, demographic, and market access factors in the emerging markets; incentive programs for pediatric studies, orphan products, and neglected diseases; and tracking the progress of new regulatory and research initiatives such as regulatory science, comparative effectiveness research, translational medicine, and personalized medicine. Dr. Milne is also research assistant professor at Tufts University Medical School, member of the editorial board of the Food & Drug Law Journal, and an honorary fellow at the University of Edinburgh.